Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The process involves the presentation of viral antigens from Newcastle disease virus by antigen-presenting cells (such as dendritic cells, macrophages, and B cells) to T lymphocytes, leading to the stimulation of adaptive immune responses. This includes the activation and differentiation of B and T lymphocytes, production of virus-specific antibodies, and generation of memory immune cells, which are essential for long-term immunity and effective vaccine responses against NDV. Various pattern recognition receptors, especially toll-like receptors (TLRs), play roles in the initial detection and activation steps. The quality and magnitude of the adaptive immune response can vary based on host genetics, viral strain, and environmental factors.
Presentation of NDV viral antigens by antigen-presenting cells (dendritic cells, macrophages, B cells) leads to activation of CD4+ and CD8+ T lymphocytes, stimulation of B cells to produce virus-specific antibodies, and induction of memory lymphocyte formation.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Immune system stimulation via presentation of viral antigens leading to adaptive immune response against Newcastle disease virus.